PIK3CA oncogenic mutations represent a major mechanism of resistance to trastuzumab in HER2/neu overexpressing uterine serous carcinomas (vol 113, pg 1020, 2015)

被引：9
|
作者：
Black, Jonathan D.
Lopez, Salvatore
Cocco, Emiliano
Bellone, Stefania
Altwerger, Gary
Schwab, Carlton L.
English, Diana P.
Bonazzoli, Elena
Predolini, Federica
Ferrari, Francesca
Ratner, Elena
Silasi, Dan-Arin
Azodi, Masoud
Schwartz, Peter E.
Santin, Alessandro D.
机构：
来源：
BRITISH JOURNAL OF CANCER | 2015年 / 113卷 / 11期
关键词：
D O I：
10.1038/bjc.2015.388
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Correction to: British Journal of Cancer (2015) 113, 1020–1026. doi:10.1038/bjc.2015.306 It has been brought to our attention that there is an error in Figure 3 of the above paper published in advance online on 1 September 2015. The original label above the figure reads as ‘ARK-2 E93Q’. It should becorrected to ‘ARK-2 R93Q’.
引用
收藏
页码：1641 / 1641
页数：1
相关论文
共 27 条
  • [21] PIK3CA Mutations Are Associated With Lower Rates of Pathologic Complete Response to Anti-Human Epidermal Growth Factor Receptor 2 (HER2) Therapy in Primary HER2-Overexpressing Breast Cancer
    Loibl, Sibylle
    von Minckwitz, Gunter
    Schneeweiss, Andreas
    Paepke, Stefan
    Lehmann, Annika
    Rezai, Mahdi
    Zahm, Dirk M.
    Sinn, Peter
    Khandan, Fariba
    Eidtmann, Holger
    Dohnal, Karel
    Heinrichs, Clemens
    Huober, Jens
    Pfitzner, Berit
    Fasching, Peter A.
    Andre, Fabrice
    Lindner, Judith L.
    Sotiriou, Christos
    Dykgers, August
    Guo, Sanxing
    Gade, Stephan
    Nekljudova, Valentina
    Loi, Sherene
    Untch, Michael
    Denkert, Carsten
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (29) : 3212 - 3220
  • [22] Acquired neratinib resistance is associated with acquisition of HER2 and PIK3CA mutations and can be overcome using potent drug combinations in HER2-positive breast cancer models.
    Veeraraghavan, Jamunarani
    Mistry, Ragini
    Nanda, Sarmistha
    Bose, Sreyashree
    Liu, Chia Chia
    Sethunath, Vidyalakshmi
    Shea, Martin J.
    Mitchell, Tamika
    Anurag, Meenakshi
    Mancini, Michael A.
    Diala, Irmina
    Lalani, Alshad S.
    Stossi, Fabio
    Osborne, C. Kent
    Rimawi, Mothaffar F.
    Schiff, Rachel
    CANCER RESEARCH, 2021, 81 (13)
  • [23] PIK3CA mutations and/or low PTEN predict resistance to combined anti-HER2 therapy with lapatinib and trastuzumab and without chemotherapy in TBCRC006, a neoadjuvant trial of HER2-positive breast cancer patients
    Contreras, A.
    Herrera, S.
    Wang, T.
    Mayer, I.
    Forero, A.
    Nanda, R.
    Goetz, M.
    Chang, J. C.
    Pavlick, A. C.
    Fuqua, S. A. W.
    Gutierrez, C.
    Hilsenbeck, S. G.
    Li, M. M.
    Osborne, C. K.
    Schiff, R.
    Rimawi, M. F.
    CANCER RESEARCH, 2013, 73
  • [24] PIK3CA mutations predict resistance to trastuzumab/pertuzumab and nab-paclitaxel in primary HER2-positive breast cancer - Massive parallel sequencing analysis of 293 pretherapeutic core biopsies of the GeparSepto study
    Loibl, S.
    Budczies, J.
    Weichert, W.
    Furlanetto, J.
    Stenzinger, A.
    Pfarr, N.
    von Minckwitz, G.
    Jackisch, C.
    Schneeweiss, A.
    Fasching, P.
    Schmatloch, S.
    Aktas, B.
    Nekljudova, V.
    Weber, K.
    Untch, M.
    Denkert, C.
    CANCER RESEARCH, 2016, 76
  • [25] PIK3CA mutations are associated with reduced pathological complete response rates in primary HER2-positive breast cancer: pooled analysis of 967 patients from five prospective trials investigating lapatinib and trastuzumab (vol 27, pg 1519, 2016)
    Loibl, S.
    Majewski, I.
    Guarneri, V.
    Nekljudova, V.
    Holmes, E.
    Bria, E.
    Denkert, C.
    Schem, C.
    Sotiriou, C.
    Loi, S.
    Untch, M.
    Conte, P.
    Bernards, R.
    Piccart, M.
    von Minckwitz, G.
    Baselga, J.
    ANNALS OF ONCOLOGY, 2018, 29 (10) : 2151 - 2151
  • [26] PIK3CA mutations are associated with reduced pathological complete response rates in primary HER2-positive breast cancer: pooled analysis of 967 patients from five prospective trials investigating lapatinib and trastuzumab (vol 27, pg 1519, 2016)
    Loibl, S.
    Majewski, I.
    Guarneri, V.
    Nekljudova, V.
    Holmes, E.
    Bria, E.
    Denkert, C.
    Schem, C.
    Sotiriou, C.
    Loi, S.
    Untch, M.
    Conte, P.
    Bernards, R.
    Piccart, M.
    von Minckwitz, G.
    Baselga, J.
    ANNALS OF ONCOLOGY, 2019, 30 (07) : 1180 - 1180
  • [27] PIK3CA mutations are associated with reduced pathological complete response rates in primary HER2-positive breast cancer: pooled analysis of 967 patients from five prospective trials investigating lapatinib and trastuzumab (vol 27, pg 1519, 2016)
    Loibl, S.
    Majewski, I
    Guarneri, V
    Nekljudova, V
    Holmes, E.
    Bria, E.
    Denkert, C.
    Schem, C.
    Sotiriou, C.
    Loi, S.
    Untch, M.
    Conte, P.
    Bernards, R.
    Piccart, M.
    von Minckwitz, G.
    Baselga, J.
    ANNALS OF ONCOLOGY, 2018, 29 (04) : 1075 - 1075
123